Charnwood Molecular unveils plans to quadruple capacity

April 2021

Download Press Release

Synova portfolio company, Charnwood Molecular, a leading UK-based outsourced drug discovery CRO servicing the global pharmaceutical and biotechnology market, has announced a milestone investment in its ambitious growth strategy. The company will become the sole occupier of a substantial 3-storey, state-of-the-art laboratory facility later this year at Charnwood Campus, Loughborough. The facility will increase Charnwood Molecualr’s physical capacity four-fold with flexible lab space supporting the company’s projected headcount growth and capability expansions. Charnwood Campus is a Science, Innovation and Technology Park set in 70 acres of landscaped grounds in Loughborough.

Charnwood Molecular has seen significant expansion of its global client base in recent years. This latest physical expansion of the company will support its growth plan across a wide range of contract research services: from medicinal chemistry, chemical development and early process research through to developing a suite of complementary services in order to provide a holistic pre-clinical discovery portfolio to its international client base.

Steve Allin, CEO of Charnwood Molecular, commented:

“The truly world-class facilities at Charnwood Campus provide us with a key piece in our strategic plan to become the provider of choice for integrated drug discovery and development services within the global life sciences sector. The new laboratories will provide substantial capacity for future growth and expansion of our medicinal chemistry and process research teams, along with the addition of related drug discovery service lines.”